Profile data is unavailable for this security.
About the company
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
- Revenue in JPY (TTM)0.00
- Net income in JPY-2.32bn
- Incorporated2016
- Employees37.00
- LocationModalis Therapeutics Corp4FY's Bldg., 16-5, Nihonbashi Kabuto-choCHUO-KU 103-0023JapanJPN
- Phone+81 368224584
- Websitehttps://www.modalistx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PhoenixBio Co Ltd | 1.72bn | 26.38m | 2.18bn | 65.00 | 151.41 | 1.21 | 66.42 | 1.27 | 3.55 | 3.55 | 409.59 | 446.27 | 0.5983 | 1.28 | 6.80 | -- | 0.9201 | -4.04 | 1.31 | -5.28 | 69.67 | 65.88 | 1.54 | -6.97 | 3.99 | -- | 0.2871 | -- | -19.24 | 6.91 | -94.65 | -- | -9.96 | -- |
Modalis Therapeutics Corp | 0.00 | -2.32bn | 2.94bn | 37.00 | -- | 2.43 | -- | -- | -72.46 | -72.46 | 0.00 | 29.59 | 0.00 | -- | -- | 0.00 | -103.95 | -29.19 | -112.89 | -30.02 | -- | -- | -- | -597.35 | 9.75 | -- | 0.2638 | -- | -100.00 | -- | 11.50 | -- | 135.50 | -- |
D.Western Therapeutics Institute Inc | 443.18m | -1.04bn | 3.06bn | 21.00 | -- | 2.92 | -- | 6.91 | -32.29 | -32.29 | 13.84 | 29.84 | 0.1784 | 0.472 | 3.10 | 21,103,950.00 | -42.16 | -13.06 | -45.11 | -14.36 | 91.32 | 94.29 | -236.36 | -72.51 | 11.65 | -- | 0.509 | -- | -4.40 | 7.90 | -89.07 | -- | 7.08 | -- |
Ribomic Inc | 0.00 | -1.02bn | 3.52bn | 24.00 | -- | 0.9767 | -- | -- | -28.70 | -28.70 | 0.00 | 94.20 | 0.00 | -- | -- | 0.00 | -25.19 | -30.52 | -26.34 | -31.71 | -- | -- | -- | -1,777.84 | 22.49 | -- | 0.00 | -- | -100.00 | -- | 38.04 | -- | 4.42 | -- |
Human Metabolome Technologies Inc | 1.34bn | 285.75m | 3.74bn | 57.00 | 13.08 | 1.94 | 10.11 | 2.79 | 48.31 | 48.31 | 226.62 | 326.17 | 0.5643 | 17.82 | 3.80 | 23,500,000.00 | 12.04 | -- | 15.43 | -- | 63.89 | -- | 21.33 | -- | 3.84 | 124.76 | 0.1061 | -- | 6.21 | -- | 6.71 | -- | -- | -- |
FunPep Co Ltd | 676.00k | -760.40m | 4.66bn | 15.00 | -- | 1.98 | -- | 6,886.95 | -31.52 | -31.52 | 0.028 | 90.56 | 0.0002 | -- | 3.39 | 45,066.67 | -26.86 | -27.10 | -28.42 | -28.75 | -- | -- | -112,484.90 | -815.82 | 17.27 | -1,006.15 | 0.00 | -- | -50.33 | -72.80 | 20.39 | -- | -13.14 | -- |
BrightPath Biotherapeutics Co Ltd | 72.00k | -1.17bn | 5.08bn | 24.00 | -- | 4.62 | -- | 70,596.71 | -18.30 | -18.30 | 0.0011 | 13.84 | 0.00005 | -- | 2.36 | 3,000.00 | -79.69 | -51.56 | -87.69 | -54.32 | 75.00 | 68.63 | -1,622,336.00 | -22,321.82 | -- | -435.39 | 0.1031 | -- | -98.64 | -78.47 | 21.37 | -- | -46.55 | -- |
Kidswell Bio Corp | 2.43bn | -1.42bn | 5.56bn | 42.00 | -- | 6.60 | -- | 2.29 | -40.81 | -40.81 | 68.79 | 21.35 | 0.5415 | 1.84 | 2.47 | 57,886,570.00 | -31.67 | -57.41 | -51.25 | -81.13 | 42.75 | 55.20 | -58.49 | -123.52 | 1.70 | -28.91 | 0.7559 | -- | -12.43 | 18.93 | -116.31 | -- | -- | -- |
Cyfuse Biomedical KK | 64.79m | -645.40m | 6.05bn | 21.00 | -- | 1.97 | -- | 93.37 | -82.27 | -82.27 | 8.26 | 378.39 | 0.0153 | 0.5202 | 13.80 | 3,085,095.00 | -15.19 | -- | -17.68 | -- | 61.81 | -- | -996.19 | -- | 6.39 | -81.61 | 0.2126 | -- | -83.68 | -- | -24.32 | -- | -- | -- |
Veritas In Silico Inc | -100.00bn | -100.00bn | 6.10bn | 15.00 | -- | 2.59 | -- | -- | -- | -- | -- | 363.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.94 | -- | 0.00 | -- | 101.54 | -- | 123.38 | -- | -- | -- |
DNA Chip Research Inc | 490.46m | -248.29m | 6.25bn | 37.00 | -- | 8.52 | -- | 12.74 | -39.09 | -39.09 | 77.17 | 108.27 | 0.5292 | 9.84 | 3.11 | 13,255,730.00 | -26.79 | -23.49 | -32.60 | -26.70 | 13.53 | 14.28 | -50.62 | -54.10 | 2.92 | -2,206.97 | 0.00 | -- | 49.74 | 6.33 | 31.48 | -- | -15.75 | -- |
Kringle Pharma Inc | 77.93m | -904.81m | 6.80bn | 13.00 | -- | 2.80 | -- | 87.27 | -159.92 | -159.92 | 13.58 | 356.64 | 0.027 | -- | 2.80 | 5,994,308.00 | -31.29 | -19.00 | -33.20 | -20.23 | -- | -- | -1,161.12 | -156.51 | 12.85 | -- | 0.00 | -- | -82.33 | -- | -157.41 | -- | -- | -- |
Chiome Bioscience Inc | 642.70m | -1.30bn | 6.99bn | 51.00 | -- | 5.54 | -- | 10.88 | -25.56 | -25.56 | 12.60 | 22.39 | 0.3348 | 4.27 | 8.96 | 12,602,040.00 | -67.53 | -50.50 | -88.83 | -57.38 | 55.96 | 57.53 | -201.70 | -224.74 | 3.46 | -629.88 | 0.2009 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Evolution Capital Management LLCas of 11 Jul 2024 | 5.85m | 15.05% |
Nikko Asset Management Co., Ltd.as of 27 Sep 2022 | 1.42m | 3.65% |
Rheos Capital Works, Inc. (Investment Management)as of 25 Apr 2023 | 1.40m | 3.59% |
Chibagin Asset Management Co. Ltd.as of 30 May 2023 | 0.00 | 0.00% |
Amundi Japan Ltd.as of 12 Sep 2022 | 0.00 | 0.00% |
Daiwa Asset Management Co. Ltd.as of 29 Aug 2022 | 0.00 | 0.00% |
Asset Management One Co., Ltd.as of 16 Sep 2022 | 0.00 | 0.00% |
FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2023 | 0.00 | 0.00% |
JPMorgan Asset Management (Japan) Ltd.as of 25 Apr 2023 | 0.00 | 0.00% |
SPARX Asset Management Co., Ltd.as of 17 Oct 2022 | 0.00 | 0.00% |